BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20220748)

  • 1. Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.
    Morganroth J; Lepor H; Hill LA; Volinn W; Hoel G
    Clin Pharmacol Ther; 2010 May; 87(5):609-13. PubMed ID: 20220748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.
    Morganroth J; Gretler DD; Hollenbach SJ; Lambing JL; Sinha U
    Expert Opin Pharmacother; 2013 Jan; 14(1):5-13. PubMed ID: 23216423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
    Malik M; van Gelderen EM; Lee JH; Kowalski DL; Yen M; Goldwater R; Mujais SK; Schaddelee MP; de Koning P; Kaibara A; Moy SS; Keirns JJ
    Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
    Kori S; Kellerman DJ; Voloshko P; Haugen G
    Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
    Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
    Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
    Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study.
    Green CL; Whellan DJ; Lambe L; Bellibas SE; Wijngaard P; Prats J; Krucoff MW
    J Cardiovasc Pharmacol; 2013 Nov; 62(5):466-78. PubMed ID: 23921301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.
    Mansbach RS; Ludington E; Rogowski R; Kittrelle JP; Jochelson P
    Clin Ther; 2011 Jul; 33(7):851-62. PubMed ID: 21722958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
    Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
    Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
    Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Sonnichsen D
    Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
    Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
    Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.
    Zhang X; Silkey M; Schumacher M; Wang L; Raval H; Caulfield JP
    J Clin Pharmacol; 2009 May; 49(5):534-9. PubMed ID: 19287043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron.
    Mason JW; Selness DS; Moon TE; O'Mahony B; Donachie P; Howell J
    Clin Cancer Res; 2012 May; 18(10):2913-21. PubMed ID: 22452942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
    Taubel J; Naseem A; Harada T; Wang D; Arezina R; Lorch U; Camm AJ
    Br J Clin Pharmacol; 2010 Apr; 69(4):391-400. PubMed ID: 20406223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
    Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.